Chibawanye Ene
Assistant Professor
The University of Texas MD Anderson Cancer Center at Houston
Department of Neurosurgery
Glioblastoma is the most common primary brain tumor in adults. Even with aggressive management that includes surgery, radiation and chemotherapy, the median survival is only 20 months. Unlike systemic cancers like melanoma, immunotherapy has not had a significant impact on the outcomes of patients with glioblastoma. Myeloid cells are central to the innate and adaptive immune response to glioblastoma. In brain tumors, we and others have shown that these cells directly elicit an anti-tumor response (phagocytosis, tumor cytolysis), release proinflammatory cytokines that recruit T-cells (e.g. IL-12), and also present tumor specific antigens at deep cervical lymph nodes resulting in tumor specific T-cell activation.
Education & Training
PhD - Cambridge University - 2012
MD - Indiana University School of Medicine - 2013